- Clinical Experience
- Rheumatology
- Pulmonology
- Ophthalmology
- Nephrology
- Neurology
- Proposed MOA
- Dosing & Duration
- Safety Data
- Acthar Patient Support
- Resources & Videos
Acthar Patient Support is available. Learn more.
Rahaghi FF, Sweiss NJ, Saketkoo LA, Scholand MB, Barney JB, Gerke AK, et al—European Respiratory Review, 2020
Disclosure statement: Publication of this peer reviewed paper was sponsored by Mallinckrodt Pharmaceuticals.
To help address the need for Acthar Gel clinical guidance, an expert panel established consensus recommendations for the use of Acthar Gel in patients with advanced sarcoidosis
Robert P. Baughman, MD University of Cincinnati Medical Center
Franck F. Rahaghi, MD, MHS, FCCP Cleveland Clinic Florida
Nadera J. Sweiss, MD, FACR University of Illinois at Chicago College of Medicine
Lesley Ann Saketkoo, MD, MPH Tulane University School of Medicine
Mary Beth Scholand, MD University of Utah Medical Center
Joseph B. Barney, MD, MSPH, FACP, FCCP University of Alabama at Birmingham
Alicia K. Gerke, MD, MBA University of Iowa Carver College of Medicine
Elyse E. Lower, MD University of Cincinnati Medical Center
Mehdi Mirsaeidi, MD University of Miami Miller School of Medicine
Lanier O’Hare, MSN, CRNP University of Alabama at Birmingham
Mark J. Rumbak, MD University of South Florida College of Medicine
Lobelia Samavati, MD Wayne State University School of Medicine
*Panelists were screened and recruited as physicians who treat patients with pulmonary sarcoidosis and met the International Committee of Medical Journal Editors criteria for authorship. International panelists were not included.
Recommended dosing from the label
Recommended dosing from expert panelists
*If patients develop major adverse events, consider reducing or discontinuing Acthar Gel.
†Not a consensus recommendation.
Sarcoidosis experts proposed the following phenotypes and treatment recommendations for sarcoidosis patients
*The panel considered several classes of adverse events including edema, anxiety/depression, infection, increased appetite or weight gain, glucose intolerance or worsening of glycemic control, hypertension, darkening of the skin, other skin-related adverse events, localized injection site pain, and insomnia.
Hear from Dr. Baughman on updated European Respiratory Society (ERS) guidelines
Findings from the US sarcoidosis expert panel consensus study, as well as the recently released ERS guidelines that include recommendations for the use of Acthar Gel.
Get the prescription and reimbursement process started
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
Acthar Gel is indicated for:
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: